Cargando…
Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
BACKGROUND: This study aimed to investigate the trend of selecting ranibizumab and aflibercept for the initial treatment of neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). METHODS: This was a retrospective study that included 460 patients who were diag...
Autores principales: | Kim, Jae-Hui, Kim, Jong-Woo, Kim, Chul-Gu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396892/ https://www.ncbi.nlm.nih.gov/pubmed/34441876 http://dx.doi.org/10.3390/jcm10163580 |
Ejemplares similares
-
Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015) -
Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021) -
SOD2 gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Kondo, Naoshi, et al.
Publicado: (2009) -
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019) -
Evaluation of the association of C5 with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Liu, Ke, et al.
Publicado: (2019)